Sergio Rius-Rocabert

Sergio Rius-Rocabert


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CCClaire Coderch
Claire Coderch
AAArranz-Herrero Arranz-Herrero
Arranz-Herrero Arranz-Herrero
ENEstanislao Nistal-Villan
Estanislao Nistal-Villan
Beatriz de Pascual-TeresaBeatriz de Pascual-Teresa
Beatriz de Pascual-Teresa
SRSergio Rius-Rocabert
Sergio Rius-Rocabert
The stimulator of interferon genes (STING) is an adaptor protein involved in the activation of IFN-β and many other genes associated with the immune response activation in vertebrates. STING induction has gained attention from different angles such as the potential to trigger an early immune response against different signs of infection and cell damage, or to be used as an adjuvant in cancer immune treatments. Pharmacological control of aberrant STING activation can be used to mitigate the pathology of some autoimmune diseases. The STING structure has a well-defined ligand binding site that can harbor natural ligands such as specific purine cyclic di-nucleotides (CDN). In addition to a canonical stimulation by CDNs, other non-canonical stimuli have also been described, whose exact mechanism has not been well defined. Understanding the molecular insights underlying the activation of STING is important to realize the different angles that need to be considered when designing new STING-binding molecules as therapeutic drugs since STING acts as a versatile platform for immune modulators. This review analyzes the different determinants of STING regulation from the structural, molecular, and cell biology points of view.

19 April 2021 in Human Gene Therapy
Verified
Journal Article
Closed access
ENEstanislao Nistal-Villan
Estanislao Nistal-Villan
JAJosepmaria Argemi
Josepmaria Argemi
AJAnchel de Jaime-Soguero
Anchel de Jaime-Soguero
RFRoberto Ferrero
Roberto Ferrero
MSMarianna di Scala
Marianna di Scala
TATomás Aragón
Tomás Aragón
Tight control of transgene expression is key to ensure the efficacy of a wide range of gene therapy interventions, in which the magnitude and duration of gene expression have to be adjusted to therapeutic needs, thereby limiting secondary effects. The development of upgraded strategies to link transgene expression to pathological stress episodes is an unmet need in gene therapy. Here, we propose an expression strategy that associates transgene expression to an intracellular stress coping mechanism, the unfolded protein response. Specifically, we harnessed the cis elements required to sustain the noncanonical splicing of X-box binding protein 1 (XBP1) messenger RNA (mRNA) in response to the dysfunction of the endoplasmic reticulum (ER), a situation commonly known as ER stress, to drive the expression of heterologous genes. Since ER stress features a wide variety of pathological conditions, including viral infections, cancer, or metabolic disorders, this new expression module stimulates the synthesis of therapeutic genes as a response to cellular damage, and ensures their expression only when necessary. Validation of this inducible expression system was performed in vitro and in vivo , and its potential to limit/inhibit viral infections has been shown in proof-of principle experiments.

29 April 2026 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
SRSergio Rius-Rocabert
Sergio Rius-Rocabert
VTVicent Tur-Planells
Vicent Tur-Planells
JAJavier Arranz-Herrero
Javier Arranz-Herrero
IIInes Inchausti-Moya
Ines Inchausti-Moya
LMLisa Miorin
Lisa Miorin
ENEstanislao Nistal-Villan
Estanislao Nistal-Villan
STING plays a pivotal role in initiating antiviral and proinflammatory responses in vertebrates. cGAS detection of cytosolic dsDNA, leads to the synthesis